Scientists at St. Jude Children’s Research Hospital developed CHANGE‑seq‑BE, an unbiased, sensitive method to map genome‑wide off‑target activity induced by base editors. Reported in Nature Biotechnology, the technique delivers efficient, resource‑light profiling and has already supported an emergency FDA request for a base‑editor therapy targeting X‑linked Hyper‑IgM syndrome, where CHANGE‑seq‑BE confirmed high on‑target specificity and negligible off‑target events. The platform aims to accelerate clinical safety evaluation for next‑generation gene‑editing therapeutics.